These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30346132)

  • 1. Pick Your Model Wisely: Understanding the Negative Symptoms of Schizophrenia in Rodent Models.
    Yohn SE; Conn PJ
    ACS Chem Neurosci; 2019 Jan; 10(1):33-35. PubMed ID: 30346132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.
    Neill JC; Harte MK; Haddad PM; Lydall ES; Dwyer DM
    Eur Neuropsychopharmacol; 2014 May; 24(5):822-35. PubMed ID: 24287012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral phenotypes for negative symptoms in animal models of schizophrenia.
    Miyamoto Y; Nitta A
    J Pharmacol Sci; 2014; 126(4):310-20. PubMed ID: 25409784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia.
    Wilson CA; Koenig JI
    Eur Neuropsychopharmacol; 2014 May; 24(5):759-73. PubMed ID: 24342774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia.
    Barnes SA; Der-Avakian A; Markou A
    Eur Neuropsychopharmacol; 2014 May; 24(5):744-58. PubMed ID: 24183826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System.
    Lee JS; Jung S; Park IH; Kim JJ
    Curr Neuropharmacol; 2015; 13(6):750-9. PubMed ID: 26630955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.
    Millan MJ; Fone K; Steckler T; Horan WP
    Eur Neuropsychopharmacol; 2014 May; 24(5):645-92. PubMed ID: 24820238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia.
    Pedersen CS; Sørensen DB; Parachikova AI; Plath N
    Behav Brain Res; 2014 Oct; 273():63-72. PubMed ID: 25064467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments.
    Foussias G; Siddiqui I; Fervaha G; Agid O; Remington G
    J Psychopharmacol; 2015 Feb; 29(2):116-26. PubMed ID: 25516370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-assessment of negative symptoms - Critical appraisal of the motivation and pleasure - Self-report's (MAP-SR) validity and reliability.
    Richter J; Hesse K; Eberle MC; Eckstein KN; Zimmermann L; Schreiber L; Burmeister CP; Wildgruber D; Klingberg S
    Compr Psychiatry; 2019 Jan; 88():22-28. PubMed ID: 30466014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits.
    Schooler NR
    Acta Psychiatr Scand Suppl; 1994; 380():21-6. PubMed ID: 7914043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative symptoms of schizophrenia: a problem that will not go away.
    Stahl SM; Buckley PF
    Acta Psychiatr Scand; 2007 Jan; 115(1):4-11. PubMed ID: 17201860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats.
    Scheggi S; Pelliccia T; Ferrari A; De Montis MG; Gambarana C
    Neuroscience; 2015 Apr; 291():189-202. PubMed ID: 25686523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.
    Carbon M; Correll CU
    CNS Spectr; 2014 Dec; 19 Suppl 1():38-52; quiz 35-7, 53. PubMed ID: 25403863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Negative Symptoms in Schizophrenia - an Overview].
    Klaus F; Kaiser S; Kirschner M
    Ther Umsch; 2018 Jun; 75(1):51-56. PubMed ID: 29909762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of schizophrenia negative symptoms: future prospects.
    Erhart SM; Marder SR; Carpenter WT
    Schizophr Bull; 2006 Apr; 32(2):234-7. PubMed ID: 16492797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotics and amotivation.
    Fervaha G; Takeuchi H; Lee J; Foussias G; Fletcher PJ; Agid O; Remington G
    Neuropsychopharmacology; 2015 May; 40(6):1539-48. PubMed ID: 25567425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anhedonia, self-experience in schizophrenia, and implications for treatment.
    Juckel G; Sass L; Heinz A
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S176-80. PubMed ID: 14677076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.
    Moore H
    Schizophr Bull; 2010 Nov; 36(6):1066-72. PubMed ID: 20870929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.